Compare Amphastar Pharmaceuticals Inc (AMPH) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Sezzle Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.94 (market cap $868.62M), while Sezzle Inc trades at $125.04 (market cap $4.32B). The key difference: Sezzle Inc is far larger — about 5× Amphastar Pharmaceuticals Inc's market cap, and Sezzle Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | SEZL | |
|---|---|---|
Market Cap | $868.62M | $4.32B |
Sector | Health | Technology |
52-Week High | $30.81 | $188.55 |
52-Week Low | $16.87 | $50.97 |
Enterprise Value | $1.27B | $4.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.86, down 2.22% today, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates with $0.91 versus $0.62 expected, but revenue growth remains modest. Valuation ratios appear reasonable with P/E of 12.08 and P/S of 1.3, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.
Outlook is cautious due to recent earnings misses and regulatory scrutiny, including an FDA warning letter. Analyst consensus leans Hold (66.67%) with limited Buy support. Key risks include competitive pressures and potential tariff impacts on generic drugs. Cash flow trends improved in 2026 with net cash flow rising to $36 million.
Sezzle (SEZL) trades at $125.06, up 5.98% with strong recent earnings performance, beating estimates for three consecutive quarters. The stock shows bearish technical signals despite robust fundamentals including 72.36% gross margins and 30.35% net income margins. Recent Q2 2026 results showed 51.7% revenue growth to $149.7 million with raised full-year guidance, though the stock experienced significant volatility following the report.
The outlook remains positive with analyst consensus target of $158.29 representing 26.6% upside, though elevated valuation multiples and technical weakness present near-term headwinds. Execution on growth initiatives and margin maintenance will be critical for sustained appreciation amid competitive fintech landscape and market volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
